Cargando…

The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study

BACKGROUND: Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function. METHODS: Eighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zachariou, A., Mamoulakis, C., Filiponi, M., Dimitriadis, F., Giannakis, J., Skouros, S., Tsounapi, P., Takenaka, A., Sofikitis, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020185/ https://www.ncbi.nlm.nih.gov/pubmed/29940933 http://dx.doi.org/10.1186/s12894-018-0377-9

Ejemplares similares

Mirabegron Alleviates the Degree of Burden Experienced by Caregivers of Older Females with Mixed or Urge Incontinence: A Prospective Study
por: Zachariou, Athanasios, et al.
Publicado: (2021)

Evaluation of overactive bladder symptoms in patients recovering from post-acute COVID-19 syndrome
por: Zachariou, A., et al.
Publicado: (2022)

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function
por: Zachariou, Athanasios, et al.
Publicado: (2017)

Evaluation of Overactive Bladder Symptoms in Patients Recovering from Post-Acute COVID-19 Syndrome
por: Zachariou, Athanasios, et al.
Publicado: (2022)

Varicoceles in Men With Non-obstructive Azoospermia: The Dilemma to Operate or Not
por: Kaltsas, Aris, et al.
Publicado: (2022)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Translation and Validation of the TANGO Nocturia Screening Tool into Greek
por: Zachariou, Athanasios, et al.
Publicado: (2021)

Translation and Validation of the Intermittent Catheterization Difficulty Questionnaire (ICDQ) into Greek
por: Zachariou, Athanasios, et al.
Publicado: (2022)

Transurethral resection of a bladder trigone leiomyoma: a rare case report
por: Zachariou, Athanasios, et al.
Publicado: (2020)

Transvaginal closure of urinary bladder opening and Mitrofanoff technique in a neurologically impaired female with chronic indwelling catheter: a case presentation
por: Zachariou, Athanasios, et al.
Publicado: (2021)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Unraveling the impact of Lactobacillus spp. and other urinary microorganisms on the efficacy of mirabegron in female patients with overactive bladder
por: Zhou, Zhipeng, et al.
Publicado: (2022)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
por: Hsiao, Sheng-Mou, et al.
Publicado: (2022)

Correction to: Transvaginal closure of urinary bladder opening and Mitrofanof technique in a neurologically impaired female with chronic indwelling catheter: a case presentation
por: Zachariou, Athanasios, et al.
Publicado: (2022)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
por: Nakagomi, Hiroshi, et al.
Publicado: (2022)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
por: Ito, Hidenori, et al.
Publicado: (2022)

Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence
por: Özkidik, Mete, et al.
Publicado: (2019)

Effects of overactive bladder syndrome on female sexual function
por: Lin, Xiao-Dan, et al.
Publicado: (2021)

Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study
por: Li, Wang, et al.
Publicado: (2023)

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy
por: Matsuo, Tomohiro, et al.
Publicado: (2018)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
por: Perk, Sinem, et al.
Publicado: (2016)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study
por: Tang, Qing-lai, et al.
Publicado: (2022)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
por: Lee, Raymond T, et al.
Publicado: (2013)

Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot study
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j0kj6qagivar0e78codo47v0k4